氯吡格雷与阿司匹林用于冠心病二级预防:系统评价与个体患者数据Meta分析
该个体患者数据Meta分析纳入7项随机试验、28982例已确诊冠心病患者(多数接受过PCI或发生过ACS),比较氯吡格雷单药与阿司匹林单药的疗效与安全性。中位随访2.3年,5.5年时氯吡格雷组MACCE发生率低于阿司匹林组(2.61 vs 2.99例/100患者年,HR 0.86,95%CI 0.77-0.96,p=0.0082);全因死亡与大出血无显著差异(大出血0.71 vs 0.77例/100患者年,HR 0.94,95%CI 0.74-1.21,p=0.64)。作者结论支持在已确诊冠心病患者二级预防中优先选用氯吡格雷而非阿司匹林。
要点
- 已确诊冠心病患者中,氯吡格雷单药较阿司匹林单药降低MACCE(心血管死亡、心肌梗死或卒中)风险:5.5年时HR 0.86(95%CI 0.77-0.96),p=0.0082。
- 氯吡格雷与大出血风险无显著差异:大出血0.71 vs 0.77例/100患者年,HR 0.94(95%CI 0.74-1.21),p=0.64。
- 全因死亡在氯吡格雷组与阿司匹林组间无显著差异。
- 纳入人群为已确诊冠心病且已停用或从未开始双联抗血小板治疗者,多数曾接受PCI或发生ACS。
- 作者结论支持在已确诊冠心病患者二级预防中优先选用氯吡格雷而非阿司匹林。
适用人群与场景
- 已确诊冠心病(CAD)且已停用或从未开始双联抗血小板治疗的患者,多数曾接受经皮冠状动脉介入治疗(PCI)或发生过急性冠脉综合征(ACS)。
研究设计与关键结果
- 研究类型:系统评价与个体患者数据Meta分析,纳入7项随机试验,共28982例患者(氯吡格雷组14507例,阿司匹林组14475例),中位随访2.3年(IQR 1.1-4.0)。
- 主要疗效终点MACCE(心血管死亡、心肌梗死或卒中)在5.5年时氯吡格雷组低于阿司匹林组:929例事件(2.61例/100患者年)vs 1062例事件(2.99例/100患者年),HR 0.86(95%CI 0.77-0.96),p=0.0082。
- 主要安全终点大出血在氯吡格雷组与阿司匹林组间无显著差异:256例事件(0.71例/100患者年)vs 279例事件(0.77例/100患者年),HR 0.94(95%CI 0.74-1.21),p=0.64。
- 全因死亡在氯吡格雷组与阿司匹林组间无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与个体患者数据Meta分析(7项随机试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论支持在已确诊冠心病患者二级预防中优先选用氯吡格雷而非阿司匹林,该结论基于个体患者数据Meta分析,适用于已停用或从未开始双联抗血小板治疗且多数曾接受PCI或发生ACS的冠心病患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Aspirin monotherapy is recommended indefinitely for patients with established coronary artery disease (CAD). The aim of this individual patient level meta-analysis was to provide a comprehensive evaluation of the comparative efficacy and safety of clopidogrel versus aspirin monotherapy in patients with established CAD, most of whom had undergone percutaneous coronary intervention or had acute coronary syndrome.
METHODS: We conducted a systematic search in PubMed, Scopus, Web of Science, and Embase to identify randomised trials published from database inception to April 12, 2025, comparing clopidogrel monotherapy with aspirin monotherapy in patients with established CAD who had discontinued or never started dual antiplatelet therapy. Randomised trials featuring an initial phase of dual antiplatelet therapy were eligible for inclusion in this individual patient data meta-analysis. In the main analysis, we used semi-parametric shared log-normal frailty models (one-stage analysis), including a random intercept to account for differences in the baseline hazard across trials, and a random slope to account for between-trial differences in treatment effects. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular or cerebrovascular events [MACCE]); the primary safety endpoint was major bleeding. This study is registered with PROSPERO (CRD42025645594).
FINDINGS: Seven randomised trials including 28 982 patients (14 507 assigned to clopidogrel; 14 475 assigned to aspirin) with a median follow-up of 2·3 years (IQR 1·1-4·0) were eligible and included. At 5·5 years, MACCE was less common in patients assigned to clopidogrel than in patients assigned to aspirin (929 events [2·61 per 100 patient-years] vs 1062 events [2·99 per 100 patient-years]; hazard ratio 0·86 [95% CI 0·77-0·96]; p=0·0082). Mortality and major bleeding (256 events [0·71 per 100 patient-years] with clopidogrel vs 279 events [0·77 per 100 patient-years] with aspirin; 0·94 [0·74-1·21]; p=0·64) did not differ.
INTERPRETATION: These findings add to the evidence that clopidogrel monotherapy is superior to aspirin monotherapy for MACCE prevention with no increase in the risk of bleeding, and support the preferential use of clopidogrel over aspirin for secondary prevention in patients with established CAD.
FUNDING: Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Switzerland.
参考来源
- Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025. PMID: 40902613. doi:10.1016/S0140-6736(25)01562-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。